NYSE:DHR

Track all markets on TradingView - Prices are not updated in real time
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.
💬
Author
WS Investor 09-16-26
Danaher reported first-quarter 2026 results showing steady revenue growth and strong earnings performance, driven by operational execution and innovation.

Revenue increased 3.5% year-on-year to $6.0 billion, while adjusted earnings per share rose 9.5% to $2.06. Net earnings totaled $1.0 billion, or $1.45 per share. The company also generated solid cash flow, with $1.3 billion in operating cash flow and $1.1 billion in free cash flow.

Performance was supported by strength in Bioprocessing and Life Sciences, partially offset by weaker demand at Cepheid due to a lighter respiratory season.

Danaher also announced plans to acquire Masimo, aiming to enhance its healthcare technology portfolio and drive long-term growth. Reflecting its strong start to the year, the company raised its full-year 2026 adjusted EPS guidance to $8.35–$8.55 while maintaining expectations for 3%–6% core revenue growth.
PRNewswire
💬
Author
European Investor 04-21-26
Danaher Corporation (NYSE: DHR) announced a quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.
💬
Author
The Investor 02-25-26
Danaher Corporation (NYSE: DHR) has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for $180 per share in cash, valuing the deal at approximately $9.9 billion, including debt.

Masimo, a specialist in pulse oximetry and patient monitoring solutions used primarily in acute care settings, will operate as a standalone business within Danaher’s Diagnostics segment alongside Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics.

Danaher expects Masimo to generate more than $530 million in EBITDA in 2027 and deliver high-single-digit core revenue growth over the long term. The transaction is projected to be accretive to adjusted diluted EPS by $0.15–$0.20 in the first full year and around $0.70 by the fifth year post-closing. Danaher also anticipates over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by year five.

The acquisition is expected to close in the second half of 2026, subject to regulatory approvals and Masimo shareholder approval. Danaher plans to finance the deal with cash on hand and debt.
Source: PRNewswire
💬
Author
The Investor 02-17-26
Danaher reported solid fourth-quarter and full-year 2025 results, supported by steady demand across its bioprocessing, diagnostics, and life sciences businesses.

In the fourth quarter, Danaher posted net earnings of $1.2 billion, or $1.66 per diluted share, while adjusted diluted EPS rose 4% year over year to $2.23. Revenue increased 4.5% to $6.8 billion, with core revenue up 2.5%. Operating cash flow reached $2.1 billion and free cash flow totaled $1.8 billion.

For full-year 2025, net earnings were $3.6 billion, or $5.03 per diluted share. Adjusted diluted EPS increased 4.5% to $7.80, while revenue grew 3% to $24.6 billion and core revenue rose 2%. Operating cash flow for the year was $6.4 billion, with free cash flow of $5.3 billion.

The company highlighted several innovation milestones in 2025, including new bioreactor formats from Cytiva, the launch of the ZenoTOF 8600 mass spectrometer by SCIEX, expanded immunoassay capabilities at Beckman Coulter Diagnostics, and FDA clearance for Cepheid’s Xpert GI Panel.

Looking ahead, Danaher expects continued gradual improvement in end markets. For the first quarter of 2026, the company anticipates low-single-digit core revenue growth year over year. For full-year 2026, core revenue growth is expected in the 3% to 6% range, with adjusted diluted EPS guidance set at $8.35 to $8.50.

Source: PR Newswire
💬
Author
WS Investor 01-28-26
Danaher to Webcast Fourth-Quarter 2025 Earnings Call on January 28

Danaher Corporation announced that it will webcast its fourth-quarter 2025 earnings conference call on Wednesday, January 28, 2026, starting at 8:00 a.m. ET. During the approximately one-hour call, the company will review its financial performance and discuss future expectations.


Source: PR Newswire
💬
Author
WS Investor 12-20-25
Danaher reported third-quarter 2025 net earnings of $908 million ($1.27 per share) and adjusted earnings of $1.89 per share, exceeding expectations. Revenue rose 4.5% year-over-year to $6.1 billion, with core revenue up 3%. Operating cash flow reached $1.7 billion, and free cash flow totaled $1.4 billion.

CEO Rainer M. Blair attributed the strong results to disciplined execution, robust performance in bioprocessing, and better-than-expected respiratory test sales at Cepheid. He said Danaher continues to invest in innovation, commercial execution, and productivity, positioning the company to address major healthcare challenges.

For full-year 2025, Danaher maintained its adjusted EPS outlook of $7.70–$7.80, expecting low single-digit core revenue growth.
💬
Author
Global Finance News 10-21-25

10 Best Stocks to Own in 2025 – Handpicked from the Morningstar Universe | Dr Wealth

10 best stocks to own in 2025 ...

(drwealth.com)
💬
Author
Global Finance News 10-21-25
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.
💬
Author
European Investor 06-18-25
Danaher Q1 2025 Earnings

- Net earnings: 954 million dollars
- GAAP earnings per share: 1.32 dollars (compared to 1.45 dollars in Q1 2024)
- Adjusted (non-GAAP) earnings per share: 1.88 dollars (compared to 1.92 dollars in Q1 2024)
- Revenue: 5.74 billion dollars, down 1.0 percent year-over-year
- Core revenue (non-GAAP): flat year-over-year
- Free cash flow: 1.06 billion dollars, down from 1.45 billion dollars in Q1 2024
- Operating cash flow: 1.3 billion dollars

Segment performance (core sales growth, non-GAAP):

- Biotechnology: up 7.0 percent
- Life sciences: down 4.0 percent
- Diagnostics: down 1.5 percent

Outlook:

- Q2 2025 core revenue growth: expected low-single digits
- Full year 2025 core revenue growth: approximately 3 percent
- Full year 2025 adjusted earnings per share guidance: 7.60 to 7.75 dollars

CEO commentary:

Rainer M. Blair stated that Danaher exceeded expectations in Q1 2025, benefiting from continued momentum in bioprocessing and stronger-than-expected respiratory demand in molecular diagnostics. Despite a dynamic macroeconomic backdrop, the company’s execution, portfolio strength, and financial position remain key differentiators.
💬
Author
Global Finance News 04-22-25
Video Thumbnail
01-09-26WS Investor
Video Thumbnail
01-21-25WS News